Veracyte, Inc. (VCYT)

NASDAQ

$43.54

+$0.70 (1.63%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$42.36$43.69

Open $42.88

52 Week Range

$22.61$50.71

Previous Close $42.84

Market Cap3.44B

Volume553.79K

Avg Volume968.60K

P/E (TTM)113.06

EPS (TTM)$0.39

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Veracyte, Inc.

NOV62025

Veracyte to Participate in Upcoming Investor Conferences

Source: Business Wire•39 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fireside ...

NOV42025

Veracyte Announces Third Quarter 2025 Financial Results

Source: Business Wire•41 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of testing ...

NOV32025

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Source: Business Wire•42 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #AfirmaGRID--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent D...

OCT152025

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Source: Business Wire•61 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, ...

SEP282025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Source: Business Wire•78 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that ...

SEP242025

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Source: Business Wire•82 days ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #ASTRO25--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy ben...